SECONAL SODIUM by Eli Lilly and Company is clinical pharmacology barbiturates are capable of producing all levels of cns mood alteration, from excitation to mild sedation, hypnosis, and deep coma. First approved in 1950.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
Seconal Sodium is a short-acting barbiturate administered by injection for CNS depression, approved in 1950 by Eli Lilly. It produces sedation, hypnosis, and anesthesia by depressing the sensory cortex and altering motor activity, with onset in 10–15 minutes and duration of 3–4 hours. The drug is used for acute sedation and anesthesia induction, though its use has declined due to abuse potential and the availability of safer modern alternatives.
Product approaching loss of exclusivity with minimal commercial activity; career opportunities are limited and primarily focused on transition and legacy account management.
CLINICAL PHARMACOLOGY Barbiturates are capable of producing all levels of CNS mood alteration, from excitation to mild sedation, hypnosis, and deep coma. Overdosage can produce death. In high enough therapeutic doses, barbiturates induce anesthesia. Barbiturates depress the sensory cortex, decrease…
Worked on SECONAL SODIUM at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Seconal Sodium offers minimal career opportunity; the zero linked job count and LOE-approaching status indicate this is a wind-down or legacy portfolio product. Professionals assigned to this product should expect focus on regulatory maintenance, safety reporting, and eventual discontinuation rather than growth or innovation.